Skip to main content
. 2021 Feb 3;118(2):413–423. doi: 10.1093/cvr/cvab032

Figure 3.

Figure 3

Graphic correlation of percent reduction in major coronary events to percent LDL-C lowering based on published data from major secondary prevention trials. Notably, statin trials are distributed along a steeper line than non-statin trials, suggesting contribution from statins’ pleiotropic effects on CV outcomes beyond pure LDL-C lowering.